Stage (next event)
Catalyst Info & Data Links
TITLE: Oraxol for Angiosarcoma Phase 2 Readout
NCT03544567: A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
08-2020 Phase 2 Primary Completion
MECHANISM OF ACTION
Paclitaxel is a widely used IV administered tubulin-stabilizing chemotherapeutic agent. By administering paclitaxel orally with encequidar, we have been able to achieve similar paclitaxel exposures compared to the widely used 80 mg/m² IV weekly dosing regimen.
Current clinical data suggests the potential of a better clinical response and tolerability profile, which can likely be attributed to the better pharmacokinetic profile achieved. Additionally, oral paclitaxel and encequidar may offer patients with paclitaxel-responsive tumors freedom from the burden of infusion clinic visits, premedication, and potentially dangerous infusion-related hypersensitivity-type reactions. Oral paclitaxel and encequidar has completed a Phase 3 pivotal trial in metastatic breast cancer, with several additional on-going clinical studies as monotherapy and in combination with other proven anticancer agents.
Read more here
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post